PBM Fraud: What the Plan Was Told and What the PBM Kept

PBM fraud uses false prices, concealed discounts or misleading reports to make a health care plan or government program pay more than it owes. The prescription may be real and the patient may receive every pill. The false account can come later, when a rebate becomes a service fee or a Medicare payment reduces the PBM’s bill for commercial business. If you know how those entries were made, you may know what the government’s payment records leave out.

How PBM Money Moves

A pharmacy benefit manager handles prescription benefits for insurers, employers and government programs. Its work can include pharmacy networks, claims processing, formulary management and manufacturer negotiations. A formulary determines which drugs the plan covers and on what terms. The PBM can influence both the pharmacy’s payment and the discounts that arrive after dispensing.

The medicine and the money take different routes. A manufacturer usually supplies a wholesaler or distributor, which supplies the pharmacy. The pharmacy sends its claim to a processor, the plan funds benefits and administration, and the patient pays any required share. Manufacturer rebates may arrive later through a rebate aggregator, while the PBM settles separate pricing commitments with the plan and pharmacies.

That leaves several accounts of the same prescription: the pharmacy’s reimbursement, the plan’s invoice, the manufacturer’s rebate and the final reconciliation. The rebate negotiator may never handle the medicine. A company under the same ownership may dispense it and earn pharmacy revenue as well.

The Federal Trade Commission’s July 2024 report found that the three largest PBMs processed nearly 80% of U.S. pharmacy prescriptions in 2023. Their integrated groups combine benefit administration, insurance and dispensing. For an insider, the important names are the entities signing the agreement, receiving the money and supplying the report.

What Does 100 Percent Pass-Through Cover?

PBM rebate pass-through can promise 100% of defined rebates while leaving other receipts outside the promise. Minnesota’s agreement effective in 2021 includes specified formulary, market-share and price-protection payments in its rebate definition. It excludes described mail and specialty purchasing discounts and specified specialty-service revenue.

The percentage sounds complete. The definition decides what it covers. Receipts outside that definition can remain revenue for the PBM or its affiliate, even under a pass-through contract. We want to know which receipts the client was promised, which business received them and what the final accounting delivered.

The party receiving a rebate may also be different from the person paying coinsurance. A discount paid to the plan after dispensing can lower the plan’s net cost while the patient’s share was calculated from an earlier price. The patient’s share of healthcare spending need not fall with the plan’s net cost.

How False Reports Reach Government Payments

Medicare Part D relies on plans to report the discounts that reduce their drug costs. Those plans use PBM information in prescription drug event summaries and separate direct and indirect remuneration reports. Leaving a rebate out can make Medicare pay against a cost the discount already reduced.

A contract can let the PBM keep a rebate. The plan still has to account for that rebate when reporting its drug costs to Medicare.

Pharmacy price concessions moved into Part D’s initial negotiated price in 2024. Later reporting still connects the estimated concession with the pharmacy’s final reimbursement. An analyst following an adjustment needs the original payment, the later remittance and the reporting entry that accounts for the difference.

The False Claims Act reaches knowingly false claims and records that matter to government payment, including claims caused through another business. For PBM cases, that connects the promised price or reporting duty to the invoice, classification or certification that changed the government’s bill. Internal explanations, warnings and decisions can show what the company understood when it supplied that information.

Medicaid can lose money after a valid prescription is dispensed to a patient who also has private coverage. Canceling the state’s reimbursement request or wrongly deducting copays can leave Medicaid paying the private plan’s share. An insider can connect the state’s request to the processing edit and the final remittance.

Who Can Explain the Missing Money?

The person who understands the discrepancy may sit at the PBM, its client, a manufacturer or a pharmacy. Contracting staff know what the agreement included and excluded. Rebate analysts see manufacturer invoices, receipts and allocations. Finance staff can explain how a credit became a service fee or reduced a liability elsewhere.

A plan actuary may notice that Medicare prices differ from the prices used in another book of business. A claims or reporting analyst can connect the pharmacy transaction to the sponsor’s extract, correction and certification. Pharmacy employees can connect a paid claim to the medicine actually supplied, while network staff know which participation terms and reimbursement rules were applied.

An audit’s scope matters just as much as its conclusion. Checking the payment at the counter can leave later concessions outside the review. The useful comparison joins the contract, invoice, pharmacy remittance, manufacturer receipt and year-end reconciliation. The person who can explain why those records disagree supplies something a stack of spreadsheets cannot.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with insiders to connect what they saw to the payment and the decisions behind it.

The PBM Fraud Patterns Behind the Reports

PBM cases can turn on an invoice, an omitted concession, a service that never happened or a price certified before enrollment. The examples below show where those representations entered the payment system and what happened when they were challenged.

Spread Pricing and Misclassified Pharmacy Costs

PBM spread pricing and disputed cost reporting were among the issues behind Ohio’s $88,289,192 settlement with Centene in 2021. Spread is the difference between what the plan pays the PBM for a prescription and what the PBM pays the pharmacy. Ohio alleged duplicated charges, undisclosed credits and costs reported under the wrong category in its Medicaid contracting chain.

For the week ending September 8, 2018, Ohio’s complaint alleged that the underlying processor billed $6,996,247 while Envolve billed Buckeye $7,395,783. It also alleged that Envolve increased a dispensing-fee line and reported the difference as pharmacy dispensing expense even though the pharmacy did not receive it. The label told the state the money had gone to dispensing. Ohio alleged that it had stayed elsewhere in the chain.

The executed Ohio settlement resolved the state’s allegations and required greater claim-level transparency. For someone working with those invoices, the revealing comparison is what the pharmacy received, what the next company billed and what the state was told the charge represented.

Manufacturer Rebates Reported as Service Fees

Rite Aid and Elixir agreed to $101 million in fixed payments in a settlement announced in July 2024 over allegedly false Medicare rebate reports. Elixir Insurance was the Part D sponsor, relying on rebate data from its PBMs.

The government alleged that retained manufacturer rebates were classified as bona fide service fees and excluded from the sponsor’s annual reports. The agreement describes retention formulas of 20% of estimated manufacturer rebates from 2014 through 2019 and 5.5% of wholesale acquisition cost for rebateable drugs in 2020.

The whistleblower’s complaint alleged that the supposed services were missing too. It calls the rebate-retaining business EPS:

We see a straightforward question beneath that label: what work did the manufacturer buy? The service agreement, work performed, retained payment and Medicare classification are different parts of the answer. A fee description cannot do the work of the service it supposedly purchased. Convenient paperwork.

Medicare Payments That Reduced a Commercial Bill

PBM cross-book pricing commitments produced a $289,873,500 judgment against three Caremark operating companies in August 2025. The court found that higher Part D pharmacy payments reduced Caremark’s commercial reconciliation obligations under pricing arrangements with Walgreens and Rite Aid. We see the upside-down bargain: higher Medicare payments helped a PBM owe pharmacies less on its commercial business.

The court’s findings treated those offsets as price concessions that the Medicare reports had to reflect. No separate refund check had to come back from a pharmacy for the concession to exist. The financial benefit appeared in the smaller obligation on the other book.

An Aetna Medicare actuary brought the case after questioning comparative drug prices. The court examined reconciliation workbooks, an internal pricing presentation and reporting attestations. An audit of point-of-sale prices had excluded direct and indirect remuneration, leaving the year-end offsets outside its scope. We would want to see the account that made the prices possible, too.

Affiliate Receipts Missing From the Plan’s Accounting

A federal employee pharmacy-benefit audit questioned $18,443,118, including investment income, in Compass Rose’s Express Scripts-administered operations. The Office of Personnel Management’s inspector general examined retail discounts, transaction credits, inventory discounts and rebates retained by Ascent. Its November 2024 report compared the money received with the plan’s contract rights.

Compass Rose disputed the audit’s retail-discount finding, while accepting other discount principles without independently validating the amounts. The report also recorded a return of $9,524,945 in rebate principal and recommended further confirmation.

For an insider following rebate aggregators and GPO fees, the manufacturer receipt is only the beginning. The affiliate’s retained amount, any credit against a pricing commitment and the plan’s final remittance show how the money was allocated. A rebate report limited to the claims-processing company can leave out the business that received the manufacturer payment.

Formulary Payments Hidden in Other Drugs’ Discounts

PBM formulary payments led to Medco‘s $7.9 million settlement over alleged kickbacks in May 2015. The Justice Department alleged that Medco accepted compensation from AstraZeneca for making Nexium the sole and exclusive proton pump inhibitor on certain formularies. Some or all of the compensation allegedly took the form of reduced prices on Prilosec, Toprol XL and Plendil.

The Medco settlement concerned claims under Medicare’s Retiree Drug Subsidy program. The alleged payment bought a position for one drug through discounts on others. A manufacturer contracting employee could understand that bargain even when the favored drug’s rebate account did not show it.

False Prices Before Enrollment

RxAmerica agreed to a $5.25 million False Claims Act settlement in 2012 over allegedly false generic-drug prices supplied to Medicare’s Plan Finder. The government alleged that prices certified during 2007 and 2008 helped beneficiaries choose plans, while later Part D claims sometimes used substantially higher prices. The price representation came before enrollment, with its consequences in later payments. For a pricing analyst, the comparison is the certified price shown to the beneficiary against the price used in the later claim.

Contracted Services That Were Not Performed

Contract representations also reach what a PBM promised to do for the plan. In its 2006 Medco announcement, the Justice Department described allegations of shorted prescriptions, canceled valid prescriptions and drug-utilization reviews that were not performed as contracted for federal employees’ benefits. A dispensing employee may know what quantity actually left the pharmacy, while a review log can show whether the promised drug check occurred. Those records can expose the gap between the contracted service and the performance report.

Pharmacy Networks and Steering

PBM pharmacy networks and steering can affect where a Part D member fills a 90-day supply and the cost sharing attached to it. Preferred status can change patient cost sharing, and specialty access can depend on both the pharmacy network and the manufacturer’s distribution arrangements. An integrated group can earn dispensing revenue at its own pharmacy as well as fees for managing the benefit.

The comparison for a network insider is the terms offered, the rule applied to the patient and the payment that followed. A claim about steering needs that connection to the client’s promise or government payment. Pharmacy reimbursement, later adjustments and affiliate receipts can each tell a different part of the story.

Types of PBM Fraud

The plan contract, pharmacy remittance and affiliate fee can give different accounts of the same prescription revenue:

• PBM Spread Pricing: When the Plan’s Charge and the Pharmacy’s Payment Diverge
• PBM Rebate Pass-Through: What the 100 Percent Promise Leaves Out
• PBM Rebate Aggregators and GPO Fees: Where the Affiliate Enters the Contract
• PBM Cross-Book Pricing Commitments: Price Concessions Without a Refund Check
• PBM Pharmacy Networks and Steering: The Promise Behind the Referral
• PBM Audits and Pharmacy Clawbacks: The Audit Kept Finding the Error
• Pharmacy Price Concessions After 2024: What Changed and What DIR Still Measures
• FEHB Pharmacy Benefit Audits: Did the Plan Receive Every Discount?
• The PBM Contract: Rebates, Pricing Commitments, Fees and Audit Rights
• PBM Integration and Specialty Pharmacy Margins: The Rebate Report Leaves Money Out
• PBM and Plan-Sponsor Whistleblowers: What the Contract Promised and the Report Left Out
• PBM Formulary Payments: When the Discount Is on a Different Drug
• PBM Reform Dates and Contract Changes: The Headline Does Not Rewrite the Contract
• PBM Fraud Cases, Audits and Settlements: Different Claims, Different Outcomes
• Pharmacy and PBM Whistleblower Rewards: The Recovery Behind the Reward
• New York PBM Pharmacy Audits: What the Audit Found and Where the Money Went
• Arkansas PBM Reimbursement Rules: What the Preemption Decisions Actually Cover

Cases

The plan pays one price while the pharmacy receives another, and the rebate can take a separate path through an affiliate. These cases examine the contract representations and payment records behind the prescription.

PBM Fraud: Spread Pricing, Rebates and Contract Representations

• Caremark: Higher Medicare Prices, a Smaller Commercial Bill
• Rite Aid and Elixir: The Rebate Settlement Behind the Service-Fee Label
• Medco: Nexium on the Formulary, Discounts on Other Drugs
• RxAmerica and CVS: Certified Prices and Later Claims
• CVS Caremark: A Prescriber Field That Identified Nobody

You Know Which Account Held the Difference

If you can explain a hidden rebate, a shifted cost or a report that left out money, speak to one of our Whistleblower Experts about where the money went. We develop your case strategy and find PBM fraud whistleblower lawyers who know rebate accounting and Medicare reporting. We stay beside you through the process to build your strongest PBM fraud whistleblower case.